TYRVAYA (varenicline) by Medica Corp. Approved for smoking cessation, nicotine dependence. First approved in 2021.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
TYRVAYA is a nasal spray formulation of varenicline approved by the FDA on October 15, 2021. Data regarding its specific indication(s) and mechanism of action are not available in the provided dataset. The product is marketed by Medica Corp and represents a novel route of administration for this active pharmaceutical ingredient.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation
Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)
Deep rTMS and Varenicline for Smoking Cessation
A Trial of Directly Observed and Long-term Varenicline
Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia
Worked on TYRVAYA at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moTYRVAYA's peak lifecycle stage and established commercial performance create opportunities for brand managers, field sales representatives, and medical science liaisons focused on market expansion and provider education. No open positions are currently linked to this product in the dataset. Success in this role requires expertise in specialty pharmacy networks, Medicare Part D formulary management, and nasal delivery device training for healthcare providers.